Cytochroma opens U.S. headquarters in Illinois
The expansion into the U.S. shall ensure that appropriate resources are available to support the Company's numerous planned clinical programs as well as subsequent U.S. product launches. Members of Cytochroma's current management team to be based in the Bannockburn office include Joel Z. Melnick, M.D., Vice President of Clinical and Regulatory Affairs and Eric J. Messner, MBA, Vice President of Commercial Operations. The Company will retain and continue growing its existing corporate headquarters in Markham.
Charles W. Bishop, PhD., President and CEO, commented, "This is an ideal time for Cytochroma to establish U.S. operations, as we move our lead programs into mid- to late-stage clinical trials and execute plans to develop our commercial infrastructure. The Chicago area is a prime location for Cytochroma, given the presence of a number of world-class pharmaceutical and healthcare companies focused on the chronic kidney disease market and the strong intellectual capital present in the region."
Cytochroma has a diverse portfolio of Vitamin D-based therapeutics designed to treat disorders related to abnormal or insufficient Vitamin D metabolism in chronic kidney disease (CKD) patients.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.